A meta-analysis of based radiomics for predicting lymph node metastasis in patients with biliary tract cancers
To assess the predictive value of radiomics for preoperative lymph node metastasis (LMN) in patients with biliary tract cancers (BTCs). PubMed, Embase, Web of Science, Cochrane Library databases, and four Chinese databases [VIP, CNKI, Wanfang, and China Biomedical Literature Database (CBM)] were sea...
Saved in:
Published in | Frontiers in surgery Vol. 9; p. 1045295 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
06.01.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | To assess the predictive value of radiomics for preoperative lymph node metastasis (LMN) in patients with biliary tract cancers (BTCs).
PubMed, Embase, Web of Science, Cochrane Library databases, and four Chinese databases [VIP, CNKI, Wanfang, and China Biomedical Literature Database (CBM)] were searched to identify relevant studies published up to February 10, 2022. Two authors independently screened all publications for eligibility. We included studies that used histopathology as a gold standard and radiomics to evaluate the diagnostic efficacy of LNM in BTCs patients. The quality of the literature was evaluated using the Radiomics Quality Score (RQS) and the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). The diagnostic odds ratio (DOR), sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and area under the receiver operating characteristic curve (AUC) were calculated to assess the predictive validity of radiomics for lymph node status in patients with BTCs. Spearman correlation coefficients were calculated, and Meta-regression and subgroup analyses were performed to assess the causes of heterogeneity.
Seven studies were included, with 977 patients. The pooled sensitivity, specificity and AUC were 83% [95% confidence interval (CI): 77%, 88%], 78% (95% CI: 71, 84) and 0.88 (95% CI: 0.85, 0.90), respectively. The substantive heterogeneity was observed among the included studies (
= 80%, 95%CI: 58,100). There was no threshold effect seen. Meta-regression showed that tumor site contributed to the heterogeneity of specificity analysis (
< 0.05). Imaging methods, number of patients, combined clinical factors, tumor site, model, population, and published year all played a role in the heterogeneity of the sensitivity analysis (
< 0.05). Subgroup analysis revealed that magnetic resonance imaging (MRI) based radiomics had a higher pooled sensitivity than contrast-computed tomography (CT), whereas the result for pooled specificity was the opposite.
Our meta-analysis showed that radiomics provided a high level of prognostic value for preoperative LMN in BTCs patients. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Reviewed by: Yawei Qian, Wuhan University, China Song Su, Affiliated Hospital of Southwest Medical University, China Edited by: Ulrich Ronellenfitsch, University Hospital Halle (Saale), Germany These authors have contributed equally to this work Abbreviations BTCs: biliary tract cancers; LMN: lymph node metastasis; CBM: China Biomedical Literature Database; RQS: Radiomics Quality Score; QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies 2; DOR: diagnostic odds ratio; PLR: positive likelihood ratio; NLR: negative likelihood ratio; AUC: area under the receiver operating characteristic curve; CI: confidence interval; MRI: magnetic resonance imaging; CT: computed tomography; ICC: intrahepatic cholangiocarcinoma; PET-CT: positron emission tomography/computed tomography; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; TP: true positive; TN: true negative; FP: false positive; FN: and false negative; sROC: summary receiver operating characteristic; ROI: region of interest; ML: logistic regression; LR: machine learning Specialty Section: This article was submitted to Surgical Oncology, a section of the journal Frontiers in Surgery |
ISSN: | 2296-875X 2296-875X |
DOI: | 10.3389/fsurg.2022.1045295 |